Please Wait
Applying Filters...
menu
    • menu
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    An Enquiry

    Evonik Health Care is the innovation hub for leading life science companies

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    An Enquiry

    Menu

    Brepocitinib

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Priovant Reports Positive Phase 2 Data For Brepocitinib
    Priovant Reports Positive Phase 2 Data For Brepocitinib

    06 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/06/3233726/34323/en/Priovant-Announces-Positive-Phase-2-Results-for-Brepocitinib-in-Cutaneous-Sarcoidosis-CS.html

    GLOBENEWSWIRE
    06 Feb 2026
    Share Share
    Priovant Advances Brepocitinib To Phase 3 In Skin Disease Study
    Priovant Advances Brepocitinib To Phase 3 In Skin Disease Study

    06 Feb 2026

    // BIOSPACE

    https://www.biospace.com/drug-development/priovant-plots-path-to-phase-3-as-brepocitinib-clears-mid-stage-skin-disease-study

    BIOSPACE
    06 Feb 2026
    Share Share
    Roivant Reports Positive Phase 2 Data For Brepocitinib
    Roivant Reports Positive Phase 2 Data For Brepocitinib

    06 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/06/3233728/34323/en/Roivant-Announces-Positive-Phase-2-Results-for-Brepocitinib-in-Cutaneous-Sarcoidosis-CS-and-Reports-Financial-Results-for-the-Third-Quarter-Ended-December-31-2025.html

    GLOBENEWSWIRE
    06 Feb 2026
    Share Share
    Priovant Will Move Brepocitinib To Phase 3 After Midstage Win
    Priovant Will Move Brepocitinib To Phase 3 After Midstage Win

    06 Feb 2026

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/pfizer-backed-priovant-scores-again-fast-rising-brepocitinib-mid-stage-study

    FIERCE BIOTECH
    06 Feb 2026
    Share Share
    Roivant Highlights Progress and Outlook at Its 2025 Investor Day
    Roivant Highlights Progress and Outlook at Its 2025 Investor Day

    11 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/11/3203811/34323/en/Roivant-Highlights-Continued-Pipeline-Progress-and-Outlook-for-Company-s-Next-Phase-of-Growth-at-2025-Investor-Day.html

    GLOBENEWSWIRE
    11 Dec 2025
    Share Share
    Roivant and Priovant to Host Investor Video Conference
    Roivant and Priovant to Host Investor Video Conference

    09 Jun 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/06/09/3096179/34323/en/Roivant-and-Priovant-to-Host-Investor-Video-Conference-at-1-00-PM-ET-on-Tuesday-June-17-on-Brepocitinib-and-the-Unmet-Medical-Need-in-Dermatomyositis.html

    GLOBENEWSWIRE
    09 Jun 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.